Summary:
- Researchers have developed an experimental vaccine that successfully triggered an immune response in patients at high risk for pancreatic ductal adenocarcinoma (PDAC).
- The study, published in *Nature*, demonstrated that the vaccine effectively trained the immune system to recognize and attack cancer-specific neoantigens, providing a promising new avenue for early intervention in one of the most lethal forms of cancer.